Older adults have more than their fair share of “old age ailments” like chronic pain, high blood pressure and diabetes or even heart conditions. These conditions often cause anxiety, insomnia, depression and other attendant ailments among this demographic, and the developments within the psychedelic space offer some promise of a reprieve to these older adults.
Of all the conditions that older people, and the population in general, suffer from, mental health challenges are the most difficult to treat. The current treatment modalities invariably mean that someone will be taking antidepressants or other drugs for months or years. Some patients even have to take these drugs for the rest of their lives.
This is where psychedelics can come in. These drugs promise a departure from the old way in which patients are in an unbreakable bond with drugs, to the new approach in which patients undergo a few treatment sessions with psychedelics. These sessions are coupled with psychotherapy before, during and after the treatment sessions using psychedelics.
The ongoing research using this method suggests that patients will not only get some relief from their symptoms, but they could have a lasting remission from the mental health condition for which they have a diagnosis.
In fact, the ongoing research is showing that the patients who are treated using a combination of psychedelics and psychotherapy are reporting that they undergo a life-changing experience which endures several weeks and even months after a single treatment session.
Such experiences could mean a lot for older adults who, as we have already mentioned, are taking lots of medication for the cocktail of ailments that they struggle with. One less group of medications that they have to take can mean all the world to these members of society.
While such a future is an enticing one, the present reality is that psychedelic drugs have not yet been approved by the FDA as recognized treatment modalities, so anyone wishing to use such products has to cough up large sums of money in order to “go on a psychedelic trip” abroad.
Companies like Compass Pathways are hard at work to get psychedelic remedies approved, so that in time, these treatments will become widely available within the U.S. healthcare system and insurance companies can cover the cost of treatment.
Such a future may look like a hippies’ fantasy, but the fact that the FDA gave psilocybin “Breakthrough Therapy” status has eased research and bodes well for the adoption of psychedelics in mainstream medicine. Could there be a better time to be a Baby Boomer or their older sibling?
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news on the latest developments in therapeutic psychedelics, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW has secured a unique strategic position in the therapeutic psychedelics market, and our team of journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the therapeutic psychedelics industry.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…
The new FDA voucher program aims to speed approval of drugs aligned with national health…
The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…
The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…
Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…
Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…